Organizers of the Aging Research & Drug Discovery (ARDD) Meeting in Boston announced multiple featured speakers from the longevity ecosystem, including Pfizer’s Ariel Feldstein, Insilico Medicine co-founder Jacqueline Lam, and former Takeda CEO Christophe Weber. The lineup also includes industry and investment leaders such as Deerfield’s Jim Flynn and OrbiMed’s Carl Gordon. The announcements reflect ARDD’s focus on translating aging biology into therapeutic development and commercial pipelines, with the program aimed at connecting clinical, regulatory, and investment decision-makers. Several of the announced speakers are tied to drug development efforts spanning multiple disease areas and platform strategies. While the announcements are not clinical readouts, they matter for biotech teams tracking where longevity R&D priorities and partnership opportunities are converging.